LFA102, a clinical-grade PRLR neutralizing antibody, failed to provide any clinical benefit in breast and prostate cancer patients [5], although insufficient dose exposure and inhibition efficacy in vivo might account for these negative results. This evidence concerns the gene PRLR and prostate carcinoma.